BetterLife Pharma Inc. Announces Pricing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
BetterLife Pharma priced a US$100 million public offering of up to 555 million common shares at CDN$0.25 per share, with an option for purchasers to buy pre-funded warrants. Net proceeds will fund the clinical development of BETR-001, including Phase 1A, 1B, and Phase 2 trials for cluster headache and migraine.
Key figures
- Deal Value Usd
- 100000000
- Offering Price
- CDN$0.25
- Shares Offered
- 555000000
- Commission percent
- 7.0%
- Gross proceeds cad
- CDN$138,750,000
- Over allotment option
- 15%
- Pre funded warrant price
- CDN$0.24999
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.